-
-
-
-
-
-
-
Vanda Pharmaceuticals opposes FDA proposal to extend drug review timelines
-
-
-
-
-
-
-
Increasing unusual call option volume: PBRA EC BGS IBRX IGV AUTL VNDA GRAL FSLY PRGS EWJ ATOM VICR XLU EDIT
-
-
-
-
-
-
-
Vanda Pharmaceuticals (VNDA) PT Raised to $22 at H.C. Wainwright
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Vanda Pharmaceuticals (VNDA)
-
-
-
-
-
-
-
Vanda publishes study showing HETLIOZ improved sleep in insomnia patients
-
-
-
-
-
-
-
Vanda Pharmaceuticals (VNDA) Tops Q1 EPS by 2c, provides guidance
-
-
-
-
-
-
-
Vanda Pharmaceuticals (VNDA) PT Raised to $20 at H.C. Wainwright
-
414,179 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

